MétaCan
Menu
Back to cohort
Record W3135044609 · doi:10.3138/canlivj-2020-0039

Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario

2021· review· en· W3135044609 on OpenAlexaffvenueabout
Brandon M. Meyers, Jennifer J. Knox, Roxanne Cosby, JR Beecroft, Kelvin Chan, Natalie G. Coburn, Jordan J. Feld, Derek J. Jonker, Aamer Mahmud, Jolie Ringash

Bibliographic record

VenueCanadian Liver Journal · 2021
Typereview
Languageen
FieldMedicine
TopicHepatocellular Carcinoma Treatment and Prognosis
Canadian institutionsUniversity of TorontoToronto General HospitalOttawa HospitalPrincess Margaret Cancer CentreCancer Care OntarioMcMaster UniversityMount Sinai HospitalSunnybrook Health Science CentreJuravinski Cancer Centre
Fundersnot available
KeywordsMedicineSorafenibRegorafenibLenvatinibCabozantinibHepatocellular carcinomaBevacizumabSystematic reviewSystemic therapyOncologyAtezolizumabMEDLINEInternal medicineLiver transplantationCancerIntensive care medicineNivolumabTransplantationColorectal cancerChemotherapy

Abstract

fetched live from OpenAlex

Background: Hepatocellular carcinoma (HCC) is a global health problem, accounting for 4.7% of all new cancer cases and 8.2% of all cancer deaths worldwide in 2018. Resection and transplantation are the only modalities that offer a cure for HCC; however, most patients are diagnosed at an advanced stage, precluding these curative treatments. A number of local (ie, ablative therapies) and/or local-regional therapies (ie, chemo-embolization) are used and followed by systemic therapy for advanced or progressive disease. Other treatments are available, but their efficacy compared with these standards is not well known. Methods: Literature searches (1/2000 to 1/2020 or 1/2005 to 1/2020, depending on the specific systematic review question) were conducted, including MEDLINE, Embase and the Cochrane Database of Systematic Reviews. Results: Over 30,000 articles were identified. In total, 49 studies were included in the systematic review. Conclusions: There is no evidence to support the addition of sorafenib to any local or regional therapy. First-line systemic therapy options for unresectable or metastatic HCC include sorafenib, lenvatinib, and atezolizumab + bevacizumab. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.021
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.074
Threshold uncertainty score0.148

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.021
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0070.006
Bibliometrics0.0120.018
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0080.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.279
Teacher spread0.230 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2021
Admission routes3
Has abstractyes

Explore more

Same venueCanadian Liver JournalSame topicHepatocellular Carcinoma Treatment and PrognosisFrench-language works237,207